Development of a Prognostic Scoring System using MYC Expression and Soluble Interleukin Receptor -2 level for Diffuse Large B-cell Lymphoma.

IF 0.9 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Yonago acta medica Pub Date : 2023-02-01 DOI:10.33160/yam.2023.02.007

Sayaka Suzuki, Satoshi Kuwamoto, Koji Kawamura, Michiko Matsushita, Toru Motokura, Yuzuru Hosoda, Masaya Maegaki, Rina Hosoda, Kentaro Hara, Yoshihisa Umekita, Tetsuya Fukuda

{"title":"Development of a Prognostic Scoring System using MYC Expression and Soluble Interleukin Receptor -2 level for Diffuse Large B-cell Lymphoma.","authors":"Sayaka Suzuki, Satoshi Kuwamoto, Koji Kawamura, Michiko Matsushita, Toru Motokura, Yuzuru Hosoda, Masaya Maegaki, Rina Hosoda, Kentaro Hara, Yoshihisa Umekita, Tetsuya Fukuda","doi":"10.33160/yam.2023.02.007","DOIUrl":null,"url":null,"abstract":"Background: Diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), is the most frequent type of lymphoid neoplasm.Methods: We investigated the relationships between clinical factors of DLBCL-NOS and MYC immunohistochemistry (IHC) staining.Results: A total of 110 patients diagnosed with DLBCL-NOS from 2012 to 2020 at Tottori University Hospital and treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy were included. IHC staining of MYC in formalin-fixed, paraffin-embedded tumor specimens was performed, and ROC-curve analysis revealed the cut-off value of the MYC positive rate as 55%. The 2-year overall survival (OS) rates of the MYC-negative and -positive groups were 84.7% vs 57.7% (P = 0.0091), and the progression-free survival rates were 77.8% vs 54.7% (P = 0.016), respectively. Multivariate analysis for OS showed prognostic significance of MYC positivity [hazards ratio (HR): 2.496; P = 0.032], and serum levels of soluble interleukin-2 receptor (sIL-2R) > 2000 U/mL (HR: 3.950; P = 0.0019), as well as age > 75 (HR: 2.356; P = 0.068). The original scoring system was developed based on these findings. By assigning one point to each item, age (> 75), MYC positivity, and sIL-2R level (> 2000), all patients were classified into three risk categories: group 1 (0 points), group 2 (1 point), and group 3 (2-3 points). The 2-year survival rates were 100%, 83.0%, and 47.1% for the groups 1, 2, and 3, respectively (P < 0.0001).Conclusion: We suggest that a prognostic scoring system using MYC expression and soluble interleukin receptor -2 level is useful for the prediction of prognosis, contributing to further stratification in DLBCL-NOS.","PeriodicalId":23795,"journal":{"name":"Yonago acta medica","volume":"66 1","pages":"56-66"},"PeriodicalIF":0.9000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937959/pdf/yam-66-56.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Yonago acta medica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.33160/yam.2023.02.007","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), is the most frequent type of lymphoid neoplasm.

Methods: We investigated the relationships between clinical factors of DLBCL-NOS and MYC immunohistochemistry (IHC) staining.

Results: A total of 110 patients diagnosed with DLBCL-NOS from 2012 to 2020 at Tottori University Hospital and treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy were included. IHC staining of MYC in formalin-fixed, paraffin-embedded tumor specimens was performed, and ROC-curve analysis revealed the cut-off value of the MYC positive rate as 55%. The 2-year overall survival (OS) rates of the MYC-negative and -positive groups were 84.7% vs 57.7% (P = 0.0091), and the progression-free survival rates were 77.8% vs 54.7% (P = 0.016), respectively. Multivariate analysis for OS showed prognostic significance of MYC positivity [hazards ratio (HR): 2.496; P = 0.032], and serum levels of soluble interleukin-2 receptor (sIL-2R) > 2000 U/mL (HR: 3.950; P = 0.0019), as well as age > 75 (HR: 2.356; P = 0.068). The original scoring system was developed based on these findings. By assigning one point to each item, age (> 75), MYC positivity, and sIL-2R level (> 2000), all patients were classified into three risk categories: group 1 (0 points), group 2 (1 point), and group 3 (2-3 points). The 2-year survival rates were 100%, 83.0%, and 47.1% for the groups 1, 2, and 3, respectively (P < 0.0001).

Conclusion: We suggest that a prognostic scoring system using MYC expression and soluble interleukin receptor -2 level is useful for the prediction of prognosis, contributing to further stratification in DLBCL-NOS.

查看原文本刊更多论文

弥漫性大b细胞淋巴瘤MYC表达和可溶性白细胞介素受体-2水平预后评分系统的建立

背景:弥漫性大b细胞淋巴瘤(DLBCL-NOS)是最常见的淋巴样肿瘤类型。方法:探讨DLBCL-NOS临床因素与MYC免疫组化(IHC)染色的关系。结果:2012 - 2020年在鸟取大学医院诊断为DLBCL-NOS并接受利妥昔单抗、环磷酰胺、阿霉素、长春新碱和强的松龙(R-CHOP)化疗的患者共110例。对福尔马林固定、石蜡包埋的肿瘤标本进行MYC免疫组化染色，roc曲线分析显示MYC阳性率临界值为55%。myc阴性组和阳性组的2年总生存率(OS)分别为84.7%和57.7% (P = 0.0091)，无进展生存率分别为77.8%和54.7% (P = 0.016)。多因素分析显示MYC阳性对OS有预后意义[危险比(HR): 2.496;P = 0.032]，血清可溶性白细胞介素-2受体(sIL-2R)水平> 2000 U/mL (HR: 3.950;P = 0.0019)，年龄> 75岁(HR: 2.356;P = 0.068)。最初的评分系统是基于这些发现开发的。根据年龄(> 75)、MYC阳性、sIL-2R水平(> 2000)各1分，将患者分为1组(0分)、2组(1分)、3组(2-3分)。1、2、3组2年生存率分别为100%、83.0%、47.1% (P < 0.0001)。结论:基于MYC表达和可溶性白细胞介素受体-2水平的预后评分系统有助于预测预后，有助于DLBCL-NOS的进一步分层。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Yonago acta medica MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

1.60

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Yonago Acta Medica (YAM) is an electronic journal specializing in medical sciences, published by Tottori University Medical Press, 86 Nishi-cho, Yonago 683-8503, Japan. The subject areas cover the following: molecular/cell biology; biochemistry; basic medicine; clinical medicine; veterinary medicine; clinical nutrition and food sciences; medical engineering; nursing sciences; laboratory medicine; clinical psychology; medical education. Basically, contributors are limited to members of Tottori University and Tottori University Hospital. Researchers outside the above-mentioned university community may also submit papers on the recommendation of a professor, an associate professor, or a junior associate professor at this university community. Articles are classified into four categories: review articles, original articles, patient reports, and short communications.